| Business Summary | | Symbollon
Pharmaceuticals,
Inc.,
formerly
known
as
Symbollon
Corporation,
is
engaged
in
the
development
and
commercialization
of
proprietary
iodine-based
pharmaceutical
agents
and
antimicrobials.
Iodine
has
been
shown
to
be
a
rapid
acting,
broad-spectrum
antimicrobial
and
an
effective
therapeutic
for
certain
pharmaceutical
applications.
The
therapeutic
index
of
a
drug
is
the
ratio
of
the
largest
safe
dose
to
the
smallest
effective
dose.
The
Company's
technology
controls
the
ratio
of
molecular
iodine
(I2)
to
the
other
inactive
species
of
iodine
typically
present
in
solution. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Symbollon
Pharmaceuticals,
Inc.
researches,
develops
and
commercializes
proprietary
iodine-based,
pharmaceutical
agents,
disinfectants,
antiseptics
and
sanitizers.
For
the
six
months
ended
6/30/01,
revenues
rose
35%
to
$110
thousand.
Net
loss
rose
38%
to
$734
thousand.
Revenues
reflect
increased
sales
of
IodoZyme.
Higher
loss
reflects
increased
costs
related
to
the
development
of
Iogen
and
higher
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Jack Kessler, Ph.D., 50 Chairman,
CEO, Sec. and Chief Scientific Officer | $176K | Paul Desjourdy, 39 Pres,
COO, Chief Financial Officer, Gen. Counsel, Treasurer, Director | 170K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|